Anti-mouse TIGIT Antibody (Clone: 10A7) | PA007279.m2a

Name: Anti-mouse TIGIT Antibody (Clone: 10A7) | PA007279.m2a
Brand: Syd Labs
SKU: PA007279.m2a
Availability: InStock

Catalog No.: PA007279.m2a | Isotype: Mouse IgG2a Kappa | In Vivo Grade

$150.00 – $900.00

Recombinant mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Details & Specifications
References

Catalog No.	PA007279.m2a
Product Name	In vivo Grade Recombinant Anti-mouse TIGIT Monoclonal Antibody (Clone: 10A7), Mouse IgG2a Kappa
Data Sheet	📄 Download Product Data Sheet (PDF)
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	VSIG9, VSTM3, WUCAM, T-cell immunoreceptor with Ig and ITIM domains, T cell immunoreceptor with Ig and ITIM domains
Summary	The in vivo grade recombinant anti-mouse TIGIT monoclonal antibody, Mouse IgG2a Kappa (clone: 10A7) was produced in mammalian cells.
Clone	10A7
Isotype	Mouse IgG2a Kappa
Specificity/Sensitivity	The in vivo grade recombinant anti-mouse TIGIT monoclonal antibody, Mouse IgG2a Kappa (clone: 10A7) specifically binds to the mouse TIGIT protein.
Applications	ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse TIGIT protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The in vivo grade recombinant anti-mouse TIGIT monoclonal antibody, Mouse IgG2a Kappa (clone: 10A7) is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant mouse IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007279.m2a: Recombinant Anti-mouse TIGIT Monoclonal Antibody (Clone: 10A7) , Mouse IgG2a Kappa

The in vivo grade recombinant anti-mouse TIGIT monoclonal antibody, Mouse IgG2a Kappa (clone: 10A7) was produced in mammalian cells.

Background of Anti-mouse TIGIT Monoclonal Antibody (Clone: 10A7)

The 10A7 antibody binds to the TIGIT protein (WUCAM, Vstm3 or VSIG9), a novel immune checkpoint receptor with inhibitory function. TIGIT is expressed on T cells and natural killer (NK) cells, and several human cancers, including melanoma, NSCLC, and colorectal cancer. Similar to PD-1, the TIGIT receptor limits antitumor immune response in cancer.

References of Anti-mouse TIGIT Monoclonal Antibody (Clone: 10A7)

1. Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Peng Zhang, et al. Biomark Res. 2024 Jan 16;12(1):7. doi: 10.1186/s40364-023-00543-z. PMID: 38229100; PMCID: PMC10790541
“As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+ T cells, CD8+ T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes (TILs). TIGIT has been associated with NK cell exhaustion in vivo and in individuals with various cancers. It not only modulates NK cell survival but also mediates T cell exhaustion.”

2. Studying TIGIT activity against tumors through the generation of knockout mice
Ahmed Rishiq, et al. Oncoimmunology. 2023 May 29;12(1):2217735. doi: 10.1080/2162402X.2023.2217735. PMID: 37261087; PMCID: PMC10228407
“The use of antibodies to block inhibitory receptors, primarily anti-PD1 and CTLA4 (known as checkpoint therapy) revolutionized cancer treatment. However, despite these successes, the majority of cancer patients do not respond to the checkpoint treatment, emphasizing the need for development of additional therapies, which are based on other inhibitory receptors. Human TIGIT is an inhibitory receptor expressed by Natural Killer (NK) and T cells and is mainly known to interact with PVR, Nectin-2, Nectin-3, and Nectin-4.”

3. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)
Shuguang Zuo, et al. EBioMedicine. 2021 Feb:64:103240. doi: 10.1016/j.ebiom.2021.103240. PMID: 33581644; PMCID: PMC7878184
“Oncolytic virotherapy with vaccinia virus (VV) can lead to effective anti-tumor immunity by turning “cold” tumors into “hot” tumors. However, its therapeutic potential is affected by the tumor’s local immunosuppressive tumor microenvironment (TME). Therefore, it is necessary to explore the use of immune checkpoint inhibitors to arm oncolytic VVs to enhance their anti-tumor efficacy.”

4. Effective Anti-tumor Response by TIGIT Blockade Associated With Fc?R Engagement and Myeloid Cell Activation
Waight AB, et al. Front Immunol. 2020 Oct 7;11:573405. doi: 10.3389/fimmu.2020.573405. PMID: 33117369; PMCID: PMC7577118
“The molecule “T cell immunoreceptor with immunoglobulin and ITIM domain,” or TIGIT, has recently received much attention as a promising target in the treatment of various malignancies. In spite of the quick progression of anti-TIGIT antibodies into clinical testing both as monotherapy and in combination with programmed cell death-1 (PD-1)-directed immune checkpoint blockade, the molecular mechanism behind the observed therapeutic benefits remains poorly understood. Here we demonstrate, using mouse tumor models, that TIGIT blocking antibodies with functional Fc binding potential induce effective anti-tumor response.”

5. Candida albicans evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT
Yoav Charpak-Amikam, et al. Nat Commun. 2022 May 5;13(1):2463. doi: 10.1038/s41467-022-30087-z. PMID: 35513379; PMCID: PMC9072312
“Candida albicans is the most common fungal pathogen and a prevalent cause of deadly bloodstream infections. Better understanding of the immune response against it, and the ways by which it evades immunity, are crucial for developing new therapeutics against it. Natural Killer (NK) cells are innate lymphocytes best known for their role against viruses and tumors.”